In the current study, we assessed the degree of CXCR4 expression in glioblastoma tissue and its possible correlation with molecular tumor markers and survival, to evaluate the potential of CXCR4 as a PET target for the diagnostic PET agent [68Ga]Ga-Pentixafor and its therapeutic variant [177Lu]Lu-Pentixather in glioblastoma patients. The gene discussed is CXCR4; the disease is neoplasm.